Symbols

LFWD

Lifeward·NASDAQ

--(--)

LFWD fundamentals

LFWD Q4 2025 Earnings

Lifeward (LFWD) released its earnings on Mar 18, 2026: revenue was 5.08M (YoY -32.66%), missed estimates; EPS was -2.85 (YoY +86.27%), missed estimates.

Revenue / YoY

5.08M

-32.66%

EPS / YoY

-2.85

+86.27%

Report date

Mar 18, 2026

LFWD Earnings Call Summary for Q4,2025

Strategic Expansion: $10M Oramed partnership for oral insulin and $10M Skelable acquisition for AI exoskeletons.
Operational Efficiency: 25% cost reduction, 22% ReWalk unit growth, and 23% cash usage decline.
Pipeline Momentum: 104 U.S. ReWalk leads, 26 AlterG backlog, and 18-24M exoskeleton launch timeline.
Financial Resilience: $16.8M cash usage vs. $21.7M prior year, $3M Oramed loan secured.

Earnings

EPS

Revenue

Revenue & Expenses

LFWD has released its 2025 Q4 earnings report, with revenue of 5.08M, reflecting a YoY change of -32.66%, and net profit of -5.35M, showing a YoY change of 65.00%. The Sankey diagram below clearly presents LFWD's revenue sources and cost distribution.

Key Indicators

Lifeward (LFWD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lifeward (LFWD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lifeward (LFWD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lifeward (LFWD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown